Tucatinib Gives PFS Boost for Metastatic Breast Cancer

The addition of the HER2 tyrosine kinase inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly increased progression-free survival (PFS) compared to a placebo plus mAb treatment for patients with HER2-positive metastatic breast cancer. The findings position it alongside trastuzumab deruxtecan and palbociclib as agents that have demonstrated impressive PFS improvements in phase III studies.